Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360828 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00360828 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT00360828, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects.
Interventions
- DRUG Irinotecan Hydrochloride (HCI) Treatment
- DRUG Continued Irinotecan Hydrochloride (HCI) Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360828
The ClinicalTrials.gov registry entry for NCT00360828 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan Hydrochloride (HCI) Treatment is the first listed.
NCT00360828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360828 about?
NCT00360828 is a clinical study titled "Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas". Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects ...
What is the current status of trial NCT00360828?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00360828?
The interventions under investigation include: Irinotecan Hydrochloride (HCI) Treatment (DRUG), Continued Irinotecan Hydrochloride (HCI) Treatment (DRUG).
Who is sponsoring clinical trial NCT00360828?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.